Deconstructing Peripheral Neuropathy and Chemo Brain
Researchers explore mechanisms of chemotherapy-related neurotoxicity at the AACR Annual Meeting 2023.
Progress Against Cancer
Researchers explore mechanisms of chemotherapy-related neurotoxicity at the AACR Annual Meeting 2023.
The FDA granted accelerated approval to the first bispecific T-cell engager to treat two types of B-cell lymphomas The U.S. Food and Drug Administration (FDA) has granted accelerated approval to epcoritamab-bysp (Epkinly) for certain...
Cancer drugs are affected by shortages, and angiogenesis inhibitors make a comeback in combination treatments.
The treatment of cutaneous melanoma has been profoundly transformed by the advent of targeted therapy and immunotherapy, which have prolonged survival in some patients with metastatic disease and reduced the risk of relapse in...
Men are increasingly opting to put off treatment for low-risk prostate cancer, and doctors say it’s a good thing.
Mammography screening recommendation pushed back to age 40, and pancreatic cancer vaccine shows promising immune response.
An increased risk of early death exists even after treatment for childhood cancer, but survivors also have the potential for decades of life after cancer.
Researchers discover a new way breast density can impact cancer risk, and CAR T-cell therapy remains out of reach for patients with HIV.
The AACR Annual Meeting 2023 set a new record this year with the number of clinical trial abstracts submitted to the meeting. More than 240 abstracts were showcased over the course of the meeting...
Although not common, a cancer diagnosis during pregnancy or the onset of a pregnancy while a woman is receiving anticancer treatment poses unique challenges. The Presidential Select Symposium at the AACR Annual Meeting 2023...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More